Department of Medical and Health Information Management, National Cerebral and Cardiovascular Centre, Suita, Japan.
Department of Medical and Health Information Management, National Cerebral and Cardiovascular Centre, Suita, Japan.
Can J Cardiol. 2022 Nov;38(11):1697-1705. doi: 10.1016/j.cjca.2022.08.002. Epub 2022 Aug 11.
This study aimed to provide real-world data on the rates, trends, and predictors of in-hospital complications and 30-day readmission following leadless pacemaker (LP) implantation.
We analysed leadless and conventional pacemaker implantations with the use of the all-payer, nationally representative Nationwide Readmissions Database from 2017 to 2019. The national trends of in-hospital mortality, in-hospital complications, and 30-day readmission rates after pacemaker implantation were analysed. Mixed-effects multivariable logistic regression analysis was performed to identify factors associated with in-hospital death and 30-day readmission in LP patients.
A total of 137,732 admissions (age 78 years, IQR 70-85 years, 5986 LP implantations) were analysed. The in-hospital mortality, overall in-hospital complication, and 30-day readmission rates after LP implantations were 5.0%, 16%, and 16%, respectively. In LP recipients, the national estimate of in-hospital mortality declined from 10.9% in the second quarter of 2017 to 4.3% in the fourth quarter of 2019 (P < 0.001). Furthermore, the national estimate of overall complications declined from 20.6% in the second quarter of 2017 to 13.0% in the fourth quarter of 2019 (P < 0.001). In LP recipients, female sex, history of chronic kidney disease, heart failure, and malnutrition were factors associated with in-hospital death.
Analysis of the nationally representative claims database from the United States showed in-hospital mortality and complication rates (for LP implantation performed during hospitalisation) of 5.0% and 16%, respectively. Although these rates showed a decreasing trend over time, ongoing surveillance is needed for the safety of LP implantation.
本研究旨在提供关于无导线起搏器(LP)植入后住院期间并发症和 30 天再入院率的真实世界数据、趋势和预测因素。
我们使用 2017 年至 2019 年全美再入院数据库(一个覆盖所有支付方的全国代表性数据库)分析了无导线和传统起搏器植入。分析了起搏器植入后住院期间死亡率、住院期间并发症和 30 天再入院率的全国趋势。采用混合效应多变量逻辑回归分析确定与 LP 患者住院期间死亡和 30 天再入院相关的因素。
共分析了 137732 例入院(年龄 78 岁,IQR 70-85 岁,5986 例 LP 植入)。LP 植入后住院期间死亡率、总体住院期间并发症和 30 天再入院率分别为 5.0%、16%和 16%。在 LP 接受者中,全国范围内 LP 植入后住院期间死亡率从 2017 年第二季度的 10.9%下降到 2019 年第四季度的 4.3%(P<0.001)。此外,全国范围内总体并发症发生率从 2017 年第二季度的 20.6%下降到 2019 年第四季度的 13.0%(P<0.001)。在 LP 接受者中,女性、慢性肾脏病史、心力衰竭和营养不良是与住院期间死亡相关的因素。
对来自美国的具有全国代表性的索赔数据库进行分析显示,LP 植入术后住院期间死亡率和并发症发生率分别为 5.0%和 16%。尽管这些比率随时间呈下降趋势,但仍需对 LP 植入的安全性进行持续监测。